Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT-Reference-Cited by-同舟云学术

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Published:2021-10-29 Issue:2 Volume:28 Page:298-307
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Tap William D.^ORCID,Singh Arun S.^ORCID,Anthony Stephen Patrick,Sterba Mike,Zhang Chao,Healey John H.^ORCID,Chmielowski Bartosz^ORCID,Cohn Allen Lee,Shapiro Geoffrey I.^ORCID,Keedy Vicki L.^ORCID,Wainberg Zev A.,Puzanov Igor,Cote Gregory M.^ORCID,Wagner Andrew J.^ORCID,Braiteh Fadi,Sherman Eric,Hsu Henry H.,Peterfy Charles,Gelhorn Heather L.,Ye Xin,Severson Paul,West Brian L.,Lin Paul S.,Tong-Starksen Sandra

Funder

Daiichi Sankyo, Inc.Plexxikon Inc.,Daiichi Sankyo,Inc.

NIHNCINCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet;2024-06

2. Prices and Trends in FDA-Approved Medications for Sarcomas;Cancers;2024-04-18

3. Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy;ACS Nano;2024-01-22

4. Medium-term Outcomes of Excision Using Surgical Microscope of Tenosynovial Giant Cell Tumors of the Hand;Anticancer Research;2023-12-30

5. Overview of Pharmacological Therapies for Diffuse Tenosynovial Giant Cell Tumor;Future Pharmacology;2023-12-01